Importantly, integrating personalized approaches is pivotal for PEG-IFN-α-2b-based therapy in clinical practice, which will provide a comprehensive and forward-looking perspective during the treatment of HBV-related cirrhosis. The gene discussed is IFNA2; the disease is Cirrhosis.